Denosumab for the prevention of osteoporotic fractures in postmenopausal women

  • Technology appraisal guidance
  • TA204
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen Health Technology Assessment Group:

  • Scotland G, Royle P, Henderson R et al. Evidence review: denosumab for the prevention of osteoporotic fractures in post-menopausal women (March 2010)

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Amgen

II) Professional/specialist and patient/carer groups:

  • British Health Professionals in Rheumatology

  • British Society for Rheumatology

  • National Osteoporosis Society

  • Primary Care Rheumatology Society

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal College of Radiographers

  • Society for Endocrinology

II) Other consultees:

  • Coventry Teaching PCT

  • Department of Health

  • NHS North Somerset

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • National Institute for Health Research Health Technology Assessment Programme

  • NHS Quality Improvement Scotland

  • Novartis

  • Pfizer

  • Roche

  • Servier

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on denosumab by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Roger Francis, Professor of Geriatric Medicine, nominated by the National Osteoporosis Society – clinical specialist

  • Professor Jon Tobias, Professor of Rheumatology and Honorary Consultant Rheumatologist, nominated by the British Society for Rheumatology – clinical specialist

  • Niki Gonty, nominated by National Osteoporosis Society – patient expert

  • Angela White, nominated by the National Osteoporosis Society – patient expert

D. The following individuals were nominated as NHS Commissioning experts by the selected PCT allocated to this appraisal. They gave their expert/NHS commissioning personal view on denosumab by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Debbie Campbell, Head of Medicines Management, selected by North Somerset Primary Care Trust – NHS Commissioning expert

E. Representatives from the following manufacturer attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Amgen